{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.4"},{"groupId":"OG001","value":"64.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"259"},{"groupId":"OG001","value":"260"}],"units":"Participants"}],"description":"Molecular response was assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).","groups":[{"description":"Tablets, oral, dasatinib 100 mg once daily (QD)","id":"OG000","title":"Dasatinib"},{"description":"Tablets, oral, imatinib 400 mg once daily (QD)","id":"OG001","title":"Imatinib"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"Planned total follow-up duration of 5 years","title":"Percentage of Participants With Major Molecular Response (MMR) at Any Time","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}